Status:
COMPLETED
Validation of Blood Biomarkers for Alzheimer's Disease
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Alzheimer Disease
Mild Cognitive Impairment
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Alzheimer's disease (AD) has gradually become one of the major global public health issues due to its prevalence, which increases with age and life expectancy, and the economic cost of caring for pati...
Detailed Description
Rationale of the project: Recent progress in the biological diagnosis of Alzheimer's disease (AD) is considerable, with the possibility, thanks in particular to ultra-sensitive tests, of having relev...
Eligibility Criteria
Inclusion
- Patients consulting in memory clinics from Montpellier, Nîmes, or Perpignan.
- Age \>= 18 years old
- CSF AD biomarkers performed for diagnostic purpose in clinical routine practice
- Having given their written and enlightened consent
- Affiliated or beneficiary of the national health insurance
Exclusion
- Contraindication or refusal of lumbar puncture
- Patient deprived of freedom, by court or administrative order, or major protected by law
- Pregnant or breastfeeding women
Key Trial Info
Start Date :
November 24 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 20 2025
Estimated Enrollment :
342 Patients enrolled
Trial Details
Trial ID
NCT05427448
Start Date
November 24 2022
End Date
May 20 2025
Last Update
December 31 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Montpellier University Hospital
Montpellier, Occitanie, France, 34000
2
Nîmes University Hospital
Nîmes, Occitanie, France, 30000
3
Perpignan Regional Hospital
Perpignan, Occitanie, France, 66000